Plain-English translation of NCT06155604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether dapagliflozin, a medication originally developed for diabetes, can help protect the kidneys of people with lupus nephritis (kidney inflammation from lupus) who are also experiencing chronic kidney disease. You would take this medication daily along with your regular lupus treatment. The researchers hope this medication will slow the progression of kidney damage and help preserve kidney function over time.
Many people with lupus-related kidney disease continue to lose kidney function even with current standard treatments, sometimes eventually needing dialysis or a kidney transplant. This medication has shown promise in protecting kidneys in other conditions, and researchers want to see if it can help prevent further kidney damage in lupus patients.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this study, you would take a daily 10 mg tablet of dapagliflozin along with your regular lupus medications. You would continue your standard treatment exactly as before—this medication is added on top of what you're already taking. You would attend clinic visits where your doctors monitor your kidney function, lupus activity, and how well you're tolerating the medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Hong Kong